

Author: Spath Brigitte Hansen Arne Bokemeyer Carsten Langer Florian
Publisher: Informa Healthcare
ISSN: 1369-1635
Source: Platelets, Vol.23, Iss.1, 2012-02, pp. : 60-68
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
High on-treatment platelet reactivity has been associated with adverse cardiovascular events in patients receiving anti-platelet agents, but the molecular mechanisms underlying this phenomenon remain incompletely understood. Succinate, a citric acid cycle intermediate, is released into the circulation under conditions of mitochondrial dysfunction due to hypoxic organ damage, including sepsis, stroke, and myocardial infarction. Because the G protein-coupled receptor (GPCR) for succinate, SUCNR1 (GPR91), is present on human platelets, we hypothesized that succinate-mediated platelet stimulation may counteract the pharmacological effects of cyclooxygenase-1 and ADP receptor antagonists. To test this hypothesis in a controlled
Related content


Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists
Current Vascular Pharmacology, Vol. 13, Iss. 5, 2015-01 ,pp. :


By Maayani Saul Schwarz Todd E. Patel Nayana D. Craddock-Royal Barbara D. Tagliente Thomas M.
Platelets, Vol. 14, Iss. 7-8, 2003-11 ,pp. :


By Judge Heather M. Buckland Robert J. Holgate Carol E. Storey Robert F.
Platelets, Vol. 16, Iss. 7, 2005-11 ,pp. :

